Development
Lantern Pharma Inc.
LTRN
$3.32
-$0.11-3.21%
NASDAQ
| 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | |
|---|---|---|---|---|---|
| Net Income | -3.16M | -4.75M | -3.87M | -3.38M | -2.26M |
| Total Depreciation and Amortization | 3.70K | 3.50K | 3.40K | 141.00K | 2.90K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 325.90K | 471.60K | 347.50K | 190.90K | 599.00K |
| Change in Net Operating Assets | -780.20K | 679.40K | -240.40K | 380.30K | -2.38M |
| Cash from Operations | -3.61M | -3.59M | -3.76M | -2.67M | -4.04M |
| Capital Expenditure | -4.80K | 0.00 | -8.90K | -7.00K | -6.70K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 236.50K | -457.20K | -952.00K | 609.80K | -67.70K |
| Cash from Investing | 231.70K | -457.20K | -960.90K | 602.90K | -74.40K |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | 0.00 | 0.00 |
| Repurchase of Common Stock | -- | -- | -- | 0.00 | 0.00 |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | -- | -- | 0.00 | 0.00 |
| Foreign Exchange rate Adjustments | -12.20K | -6.40K | -5.00K | 9.90K | 7.60K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -3.39M | -4.06M | -4.72M | -2.06M | -4.11M |